Ibezapolstat is a small molecule commercialized by Acurx Pharmaceuticals, with a leading Phase II program in Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ibezapolstat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ibezapolstat is expected to reach an annual total of $20 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ibezapolstat (ACX-362E) is under development for the treatment of Clostridium difficile Infections. The drug candidate is administered through oral route in the form of capsules. It acts by targeting DNA polymerase IIIc. Th drug candidate is an analog of 2-deoxyguanosine 5-triphosphate (dGTP).
Acurx Pharmaceuticals Overview
Acurx Pharmaceuticals, LLC, (formerly Ampex Pharmaceuticals), a biopharmaceutical company that focused on developing new antibiotics for difficult to treat infections. The company is headquartered in United States.
The operating loss of the company was US$12.1 million in FY2022, compared to an operating loss of US$12.8 million in FY2021. The net loss of the company was US$12.1 million in FY2022, compared to a net loss of US$12.8 million in FY2021.
For a complete picture of Ibezapolstat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.